Overview
Investment firm supporting sustainable private company growth.
Founded
2008
Deals ยท 12mo
3
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Gilgamesh Pharmaceuticals | May 2026Led | $60 MSeries A | |
NextSense | Nov 2025Participated | $16 MSeries A | |
Ampa | Oct 2025Participated | $9 MSeries A | |
Holobiome | Oct 2024Participated | $9 MSeed | |
Hoodie Analytics | Jun 2024Participated | $5 MSeries A | |
Motif Neurotech | Jan 2024Participated | $19 MSeries A | |
TARA Mind | Jan 2024Led | $8 MSeed | |
Lykos Therapeutics | Jan 2024Participated | $100 MSeries A | |
Journey Clinical | Jan 2023Participated | $9 MSeries A | |
Gilgamesh Pharmaceuticals | Dec 2022Participated | $39 MSeries B | |
Bond Pet Foods | Sep 2022Participated | $18 MSeries A | |
Redbud Brands | May 2022Led | $46 MOther Equity | |
Gilgamesh Pharmaceuticals | May 2026Led | $60 MSeries A | |
NextSense | Nov 2025Participated | $16 MSeries A | |
Ampa | Oct 2025Participated | $9 MSeries A | |
Holobiome | Oct 2024Participated | $9 MSeed | |
Hoodie Analytics | Jun 2024Participated | $5 MSeries A | |
Motif Neurotech | Jan 2024Participated | $19 MSeries A | |
TARA Mind | Jan 2024Led | $8 MSeed | |
Lykos Therapeutics | Jan 2024Participated | $100 MSeries A | |
Journey Clinical | Jan 2023Participated | $9 MSeries A | |
Gilgamesh Pharmaceuticals | Dec 2022Participated | $39 MSeries B | |
Bond Pet Foods | Sep 2022Participated | $18 MSeries A | |
Redbud Brands | May 2022Led | $46 MOther Equity |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 1 |
| Series A | 1 | 7 |
| Series B | 0 | 1 |
| Other Equity | 2 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jun '17 | 1 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 1 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 3 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 11 |
| Consumer & Lifestyle | 3 |
| Networks, Cloud & Communication | 2 |
| E-Commerce & Retail | 2 |
| Hardware & Robotics | 1 |
| Marketing & Advertising | 1 |
| Education & Workforce | 1 |
| Data, Analytics & IT | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 5 |
| $10M-$25M | 4 |
| $25M-$50M | 2 |
| $50M-$100M | 1 |
| $100M-$250M | 1 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 13 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Empath Ventures | 2 |
| iSelect Fund | 2 |
| Palo Santo | 2 |
| Prime Movers Lab | 2 |
| PsyMed Ventures | 2 |
| Acclarity (Stage 1 Fund) | 1 |
| ADM | 1 |
| AlleyCorp | 1 |
| Alumni Ventures | 1 |
| Arboretum Ventures | 1 |
| Arcview Ventures | 1 |
| Ascension Ventures | 1 |
| Astanor Ventures | 1 |
| Bail Capital | 1 |
| Capital Factory | 1 |
| Cavallo Ventures | 1 |
| Coalition Operators | 1 |
| Colibri Ventures | 1 |
| Continuum Health Ventures | 1 |
| Corundum Neuroscience Fund | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 4 | 31% |
| Participating | 9 | 69% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 75% |
| Co-led | 1 | 25% |
Team
Partner & Principal Biologist
Director - Business Development
Vice President of Finance
Partner
Managing Director
Managing Partner
Principal, General Counsel, and Investment Committee Member
Managing Partner
Chief Financial Officer
